Huawei will build first digital robot for pharmaceutical industry

Huawei will build the industry’s first digital robot with China’s National Pharmaceutical Group, Sinopharm for the pharmaceutical industry. This is a brand new progress made by the Chinese tech maker to advance its growth in digital robot technologies.

In 2019, Sinopharm began to explore digital robot technology. Several subsidiaries have implemented more than 200 business processes. There are problems such as scattered business scenarios, the inability to share robot resources, and inconsistent business processes. In order to solve some problems in the early testing, open up resource sharing, unify and optimize business processes, and realize the digitalization of deep integration of operations and business.

In 2022, Sinopharm joined hands with Huawei’s digital robot team and Huawei partners. This partnership focuses on key points such as customers, data, and business elements, sorted out the business process, and planned and built the first digital robot competence center platform in the domestic pharmaceutical industry.

Relying on the large-scale application capabilities of Huawei’s WeAutomate digital robots and mature product capabilities, Sinopharm has built a digital robot capability center platform that can meet the automation application needs of thousands of subsidiaries of the group.

After the launch, all subsidiaries of Sinopharm Holdings can share common tech in business processes, and share digital robot resources in a unified and intensive manner. In addition, the Sinopharm Digital Robotics Competence Center can fully support the group’s common situations and the personalized scenarios of the branch companies.

The common scene process is uniformly constructed by the headquarters and can be used by all branch companies. On the other hand, the custom scene process is customized and shared by the branch companies.

In the future, Huawei’s WeAutomate digital robot will continue to provide technological advantages and help Sinopharm to promote more general scenarios of digital robots to all sub-companies. On the basis of realizing the sharing of digital robot resources, it will simultaneously leverage the innovation capabilities of branch companies to meet business needs.

The process of implementing Huawei’s digital robots is also a process of normalizing and standardizing the general scenarios of branch companies, which promotes the optimization and unification of Sinopharm’s business processes. After the launch of the Sinopharm Digital Robotics Competence Center, the efficiency of the online robot business scenarios can be increased by up to 25 times, and the average efficiency can be increased by more than 10 times, effectively releasing digital momentum.

Sinopharm Holdings Co., Ltd. was established in Shanghai in January 2003 and listed in Hong Kong in September 2009. It includes two A-share listed companies, Sinopharm Group Pharmaceutical Co., Ltd. and Sinopharm Accord Pharmaceutical Co., Ltd., with a total of more than a thousand subsidiaries.

Now it has become a leading distributor and retailer of pharmaceuticals, healthcare products, and medical devices in China, as well as a leading supply chain service provider. Sinopharm ranks 22nd among Fortune China’s Top 500 in 2021.